{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:11Z","timestamp":1792716911201,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Although there are evidence-based guidelines for actinic keratosis management, selecting a cost-effective field therapy is challenging because of limited studies comparing cost, efficacy, and adherence among treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To review the literature on field-directed therapies for actinic keratosis, comparing efficacy, cost, and adherence data for topical and in-office treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, and Google Scholar databases were searched from October 2020 to March 2021 for articles on field therapy for actinic keratosis. Total cost per regimen was estimated using wholesale acquisition cost package prices and Medicare coverage rates for May 2021. Effective cost was approximated by dividing total cost by complete response rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Efficacy data for various field therapies range widely, and long-term follow-up is limited. Cross-study comparisons are challenging because of heterogeneity of studies. Field-directed therapy with topical 5-fluorouracil and photodynamic therapy have similar effective cost. Adherence may significantly affect real-world efficacy and long-term clearance; this would favor shorter duration topical regimens or in-office procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Standardization of future studies examining efficacy of field treatments for actinic keratosis will allow comparison across treatments. In-office treatments such as photodynamic therapy represent a cost-effective alternative to topical therapies with comparable efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000003677","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:24:40Z","timestamp":1675347880000},"page":"124-129","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Field Therapy for Actinic Keratosis: A Structured Review of the Literature on Efficacy, Cost, and Adherence"],"prefix":"10.1097","volume":"49","author":[{"given":"Nathaniel","family":"Lampley","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rigo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[{"name":"Clinical Research Center of the Carolinas, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York, New York"},{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12955-015-0295-4","article-title":"Health related quality of life in patients with actinic keratosis\u2014an observational study of patients treated in dermatology specialist care in Denmark","volume":"13","author":"Tennvall","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"R2-20260930","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jaad.2009.02.022","article-title":"Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) trial","volume":"61","author":"Weinstock","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","article-title":"The burden of skin diseases: 2004","volume":"55","author":"Bickers","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamadermatol.2018.3086","article-title":"Use and cost of actinic keratosis destruction in the medicare part b fee-for-service population, 2007 to 2015","volume":"154","author":"Yeung","year":"2018","journal-title":"JAMA Dermatol."},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2020.03.126","article-title":"Field cancerization: definition, epidemiology, risk factors, and outcomes","volume":"83","author":"Willenbrink","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jaad.2016.12.043","article-title":"The burden of skin disease in the United States","volume":"76","author":"Lim","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaad.2018.02.058","article-title":"Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis","volume":"79","author":"Yoon","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jaad.2012.09.052","article-title":"Prevalence and awareness of actinic keratosis: barriers and opportunities","volume":"68","author":"Rosen","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"331","author":"Marks","year":"1988","journal-title":"The Lancet"},{"key":"R10-20260930","first-page":"415","article-title":"Actinic keratosis as a marker of field cancerization in excision specimens of cutaneous malignancies","volume":"97","author":"Lanoue","year":"2016","journal-title":"Cutis."},{"key":"R11-20260930","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/09546634.2019.1682504","article-title":"Contemporary management of actinic keratosis","volume":"32","author":"Navarrete-Dechent","year":"2019","journal-title":"J Dermatol Treat"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1708701","article-title":"Update on keratinocyte carcinomas","volume":"379","author":"Nehal","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.14852","article-title":"Current perspective on actinic keratosis: a review","volume":"177","author":"Siegel","year":"2017","journal-title":"Br J Dermatol."},{"key":"R15-20260930","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","article-title":"Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum\u2013short version","volume":"29","author":"Werner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMoa1811850","article-title":"Treatment approaches for actinic keratosis. Reply","volume":"380","author":"Jansen","year":"2019","journal-title":"N Engl J Med."},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2020.03.127","article-title":"Field cancerization: treatment","volume":"83","author":"Cornejo","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","article-title":"Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial","volume":"154","author":"Weinstock","year":"2018","journal-title":"JAMA Dermatol."},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40273-016-0462-4","article-title":"Pharmacoeconomic considerations in treating actinic keratosis: an update","volume":"35","author":"Vale","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2017.07.056","article-title":"Trends in Medicare spending on topical immunomodulators and chemotherapies","volume":"78","author":"Song","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N Engl J Med."},{"key":"R22-20260930","first-page":"Cd004415","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane database Syst Rev."},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"e12822","DOI":"10.1111\/dth.12822","article-title":"Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis","volume":"32","author":"Wu","year":"2019","journal-title":"Dermatol Ther"},{"key":"R24-20260930","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of care for the management of actinic keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R25-20260930","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaad.2022.04.013","article-title":"Focused update: guidelines of care for the management of actinic keratosis","volume":"87","author":"Eisen","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"R29-20260930","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2008.562","article-title":"Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses","volume":"145","author":"Yentzer","year":"2009","journal-title":"Arch Dermatol."},{"key":"R30-20260930","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","article-title":"Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis","volume":"24","author":"Loven","year":"2002","journal-title":"Clin Ther."},{"key":"R31-20260930","first-page":"629","article-title":"Short incubation PDT versus 5-FU in treating actinic keratoses","volume":"2","author":"Smith","year":"2003","journal-title":"J Drugs Dermatol."},{"key":"R32-20260930","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-2-or 4-week treatment in patients with actinic keratosis","volume":"70","author":"Jorizzo","year":"2002","journal-title":"Cutis."},{"key":"R33-20260930","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 trials of tirbanibulin ointment for actinic keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N Engl J Med."},{"key":"R34-20260930","first-page":"1278","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies","volume":"12","author":"Swanson","year":"2013","journal-title":"J Drugs Dermatol."},{"key":"R35-20260930","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas J Dermatol."},{"key":"R36-20260930","first-page":"401","article-title":"Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze)","volume":"3","author":"Nelson","year":"2004","journal-title":"J Drugs Dermatol."},{"key":"R37-20260930","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2230.2010.03999.x","article-title":"Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses","volume":"36","author":"Akarsu","year":"2011","journal-title":"Clin Exp Dermatol."},{"key":"R38-20260930","first-page":"1218","article-title":"Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis","volume":"15","author":"Dohil","year":"2016","journal-title":"J Drugs Dermatol."},{"key":"R39-20260930","first-page":"144","article-title":"Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp","volume":"6","author":"Tanghetti","year":"2007","journal-title":"J Drugs Dermatol."},{"key":"R40-20260930","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol."},{"key":"R41-20260930","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/jdv.15085","article-title":"Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance","volume":"32","author":"Ferr\u00e1ndiz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R42-20260930","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bjd.14498","article-title":"A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(\u00ae) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(\u00ae) lamp","volume":"175","author":"Reinhold","year":"2016","journal-title":"Br J Dermatol."},{"key":"R43-20260930","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","article-title":"Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial","volume":"161","author":"Gebauer","year":"2009","journal-title":"Br J Dermatol."},{"key":"R44-20260930","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo","volume":"166","author":"Dirschka","year":"2012","journal-title":"Br J Dermatol"},{"key":"R45-20260930","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"R46-20260930","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjd.16048","article-title":"Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp","volume":"178","author":"Stockfleth","year":"2018","journal-title":"Br J Dermatol"},{"key":"R47-20260930","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","article-title":"Photodynamic therapy with BF\u2010200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study","volume":"163","author":"Szeimies","year":"2010","journal-title":"Br J Dermatol."},{"key":"R48-20260930","doi-asserted-by":"crossref","first-page":"e96829","DOI":"10.1371\/journal.pone.0096829","article-title":"A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe","volume":"9","author":"Vegter","year":"2014","journal-title":"PLoS One"},{"key":"R49-20260930","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/PPA.S47126","article-title":"Non-adherence to topical treatments for actinic keratosis","volume":"8","author":"Carr","year":"2013","journal-title":"Patient Preference and Adherence"},{"key":"R50-20260930","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2021.2779","article-title":"Evaluation of long-term clearance rates of interventions for actinic keratosis: a systematic review and network meta-analysis","volume":"157","author":"Steeb","year":"2021","journal-title":"JAMA Dermatol."},{"key":"R51-20260930","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13643-019-1156-8","article-title":"Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis","volume":"8","author":"Steeb","year":"2019","journal-title":"Syst Rev"},{"key":"R52-20260930","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamadermatol.2019.4212","article-title":"Core outcome set for actinic keratosis clinical trials","volume":"156","author":"Reynolds","year":"2020","journal-title":"JAMA Dermatol."}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000003677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:46Z","timestamp":1790794846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000003677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003677","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2022-09-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}